1. Home
  2. FOLD vs OGN Comparison

FOLD vs OGN Comparison

Compare FOLD & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FOLD
  • OGN
  • Stock Information
  • Founded
  • FOLD 2002
  • OGN 1923
  • Country
  • FOLD United States
  • OGN United States
  • Employees
  • FOLD 499
  • OGN N/A
  • Industry
  • FOLD Biotechnology: Pharmaceutical Preparations
  • OGN Biotechnology: Pharmaceutical Preparations
  • Sector
  • FOLD Health Care
  • OGN Health Care
  • Exchange
  • FOLD Nasdaq
  • OGN Nasdaq
  • Market Cap
  • FOLD 2.5B
  • OGN 2.7B
  • IPO Year
  • FOLD 2007
  • OGN N/A
  • Fundamental
  • Price
  • FOLD $8.42
  • OGN $9.25
  • Analyst Decision
  • FOLD Strong Buy
  • OGN Buy
  • Analyst Count
  • FOLD 9
  • OGN 3
  • Target Price
  • FOLD $26.44
  • OGN $17.33
  • AVG Volume (30 Days)
  • FOLD 5.3M
  • OGN 3.3M
  • Earning Date
  • FOLD 11-05-2025
  • OGN 10-30-2025
  • Dividend Yield
  • FOLD N/A
  • OGN 0.86%
  • EPS Growth
  • FOLD N/A
  • OGN N/A
  • EPS
  • FOLD N/A
  • OGN 2.69
  • Revenue
  • FOLD $571,160,000.00
  • OGN $6,281,000,000.00
  • Revenue This Year
  • FOLD $21.04
  • OGN N/A
  • Revenue Next Year
  • FOLD $21.34
  • OGN $0.79
  • P/E Ratio
  • FOLD N/A
  • OGN $3.45
  • Revenue Growth
  • FOLD 25.35
  • OGN N/A
  • 52 Week Low
  • FOLD $5.51
  • OGN $8.01
  • 52 Week High
  • FOLD $12.65
  • OGN $19.05
  • Technical
  • Relative Strength Index (RSI)
  • FOLD 57.84
  • OGN 33.08
  • Support Level
  • FOLD $7.87
  • OGN $9.14
  • Resistance Level
  • FOLD $8.49
  • OGN $9.72
  • Average True Range (ATR)
  • FOLD 0.37
  • OGN 0.33
  • MACD
  • FOLD -0.03
  • OGN -0.16
  • Stochastic Oscillator
  • FOLD 81.67
  • OGN 5.10

About FOLD Amicus Therapeutics Inc.

Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.

About OGN Organon & Co.

Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.

Share on Social Networks: